ライフサイエンスコーパス: sodium thiosulfate

1 um diethyldithiocarbamate or disulfiram, and sodium thiosulfate.

2 with calciphylaxis who were treated with IL sodium thiosulfate.

3 L soap, 15 mg/L sodium iodide, and 6000 mg/L sodium thiosulfate.

4 Participants received sodium thiosulfate 16 g/m(2) intravenously 6 h after eac

5 mg/m2) at 42 degrees C and then intravenous sodium thiosulfate (16 g/m2 over 6 hours).

6 cutaneous calciphylaxis were treated with IL sodium thiosulfate (250 mg/mL) in areas of clinically ac

7 ents received cisplatin (150 mg/m(2) IA with sodium thiosulfate 9 g/m(2) intravenous [IV], followed b

8 sodium omadine, an antimicrobial agent, and sodium thiosulfate, a dechlorinating agent, over eight a

9 The combined use of polysulfide and sodium thiosulfate allows us to observe a 25x increase i

10 is needed to define the appropriate role for sodium thiosulfate among emerging otoprotection strategi

11 gated performing a series of titrations with sodium thiosulfate and potassium cyanide monitored by NM

12 Therapy involving magnesium or sodium thiosulfate appears most promising, but evaluable

13 dual function precursor ligand that bears a sodium thiosulfate (Bunte salt) group that links to the

14 Trials involving magnesium and sodium thiosulfate consistently showed attenuation of va

15 trathin sulfurous layer is formed on gold by sodium thiosulfate electro-oxidation and serves both as

16 ercalciuric rats normal food with or without sodium thiosulfate for 18 wk and measured urine chemistr

17 The primary aim of this study was to assess sodium thiosulfate for prevention of cisplatin-induced h

18 ed trials testing the efficacy and safety of sodium thiosulfate for recurrent kidney stones in humans

19 28.6%; 95% CI 16.6-43.3) participants in the sodium thiosulfate group compared with 31 (56.4%; 42.3-6

20 hearing loss was significantly lower in the sodium thiosulfate group compared with the control group

21 (117 [66%] of 177 participant cycles in the sodium thiosulfate group vs 145 [65%] of 223 in the cont

22 The use of topical sodium thiosulfate has been successfully reported for su

23 omes have been demonstrated with intravenous sodium thiosulfate; however, the use of this medication

24 Further research to determine the safety of sodium thiosulfate in patients with metastatic cancer is

25 ethyldithiocarbamate or disulfiram, systemic sodium thiosulfate, intratympanic therapies, and cisplat

26 Sodium thiosulfate is an antioxidant shown in preclinica

27 Intralesional sodium thiosulfate may be an effective and well-tolerate

28 ore, we hypothesized that intralesional (IL) sodium thiosulfate may be an effective treatment for the

29 Sodium thiosulfate may be used as the sulfur source, whi

30 rin for warfarin (n = 13 [72%]), intravenous sodium thiosulfate (n = 9 [50%]), and hyperbaric oxygen

31 articipants were randomly assigned to either sodium thiosulfate (n=61) or observation (n=64).

32 ts were assessable for the primary endpoint (sodium thiosulfate, n=49; control, n=55).

33 reported in 26 participants who had received sodium thiosulfate, none were deemed probably or definit

34 te stone formation, we studied the effect of sodium thiosulfate on urine chemistries and stone format

35 etry were randomly assigned (1:1) to receive sodium thiosulfate or observation (control group) in add

36 Depending on the reaction, sodium thiosulfate pentahydrate (Na2S2O3.5H2O), S8/KF, a

37 method for the synthesis of aryl amides from sodium thiosulfate pentahydrate, organic anhydrides, and

38 INTERPRETATION: Sodium thiosulfate protects against cisplatin-induced he

39 Sodium thiosulfate protects against cisplatin-induced he

40 In summary, sodium thiosulfate reduces calcium phosphate stone forma

41 An uncontrolled trial reported that sodium thiosulfate reduces formation of calcium kidney s

42 mide is markedly enhanced by coadministering sodium thiosulfate (reducing the total injected volume),

43 is further promoted by the presence of bulk sodium thiosulfate serving as a Lewis base, which drasti

44 oximately 1.4 mL each of nitrocobinamide and sodium thiosulfate should rescue a human from a lethal c

45 Paediatric trials assessing sodium thiosulfate showed efficacy in terms of hearing p

46 Treatment with sodium thiosulfate (STS) blocked carboplatin cytotoxicit

47 proval of a pediatric formula of intravenous sodium thiosulfate (STS) for otoprotection by the US Foo

48 nd ethylenediaminetetraacetic acid (EDTA) to sodium thiosulfate (STS) for their ability to chelate ca

49 Sodium thiosulfate (STS) is considered a potential otopr

50 fective treatment for cisplatin ototoxicity, sodium thiosulfate (STS), while beneficial when used in

51 sinter mineralogy were dominated by borates, sodium, thiosulfate, sulfate, sulfite, sulfide, bicarbon

52 ients who had disseminated disease receiving sodium thiosulfate than among controls, but not among th

53 Regarding systemic sodium thiosulfate, the panel made a strong recommendati

54 ere deemed probably or definitely related to sodium thiosulfate; the most common serious adverse even

55 idoxime, sodium bicarbonate, sodium nitrite, sodium thiosulfate, vasodilators, and vasopressors for t

56 When NAC, with or without sodium thiosulfate, was administered via aortic infusion

57 the thiol agents N-acetylcysteine (NAC) and sodium thiosulfate were administered into the descending

58 y, supplementing the medium with catalase or sodium thiosulfate yielded a significant reduction in va